The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COSTEM 2019 | Tisagenlecleucel for R/R DLBCL
Stephen Schuster, MD, University of Pennsylvania, Philadelphia, PA, talks on his study regarding tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients without measurable disease at infusion, outlining the main methods, aims and findings of the trial. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
